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Abstract
Background: The clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)
positive granulomatosis with polyangiitis (GPA) remain unclear, as does the difference between MPO-ANCA
positive GPA and proteinase 3 (PR3)-ANCA positive GPA, especially with regard to the details of respiratory tract
involvement. We investigated the differences in clinical, radiological, and histopathological features between
PR3-ANCA positive GPA and MPO-ANCA positive GPA.
Methods: We retrospectively reviewed 16 patients who were newly diagnosed with GPA between December 2000
and July 2014. One patient, who was positive for both PR3-ANCA and MPO-ANCA, was excluded. Our review was
based on the European Medicine Agency (EMA) algorithm.
Results: Fifty-six percent of GPA patients were positive for PR3-ANCA, 38 % for MPO-ANCA, and the remaining 6 %
for both. The MPO-ANCA positive group included a greater number of females (67 %). There were no statistically
significant differences in laboratory data, symptoms and signs, Birmingham Vasculitis Activity Score, or CT findings
between the two groups. As for upper respiratory tract involvement, the most common manifestation was
paranasal sinusitis, whereas lung nodules were most common as the lower respiratory tract involvement in both
groups. Although the combination therapy with prednisone and cyclophosphamide was the most common initial
treatment in both groups, the relapse rate in MPO-ANCA positive cases was lower than that of PR3-ANCA positive
cases (17 % and 56 %, respectively).
Conclusion: A high prevalence of MPO-ANCA positive GPA was noted. No significant differences in clinico-radiological
findings were observed except for the prevalence of relapse between the PR3-ANCA positive cases and MPO-ANCA
positive cases, suggesting that the type of ANCA may be of little help in the diagnosis of GPA. Examination for
granulomatous findings in the respiratory tract is important, even in MPO-ANCA positive cases. There is a need to
accumulate more cases and conduct a further investigation in the future.
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Background
Granulomatosis with polyangiitis (GPA) is a systemic
vasculitis syndrome characterized by necrotizing granu-
lomatous inflammation of the respiratory tracts, systemic
necrotizing vasculitis, and necrotizing glomerulonephritis
[1]. In 1990, the classification criterion, established with
the combination of clinical characteristics and pa-
thological characteristics, was reported by the American
College of Rheumatology (ACR) [2], and this was followed
by the Chapel Hill Consensus Conference (CHCC),
wherein the classification was established from a patho-
logical perspective [3]. In 2007, the European Medicine
Agency (EMA) proposed a multi-stage classification algo-
rithm of antineutrophil cytoplasmic antibody (ANCA)-as-
sociated vasculitis (AAV) and classic polyarteritis nodosa
(PN) using ACR classification criteria, CHCC classifica-
tion, and surrogate markers for vasculitis and ANCA, with
the aim of applying the classification in epidemiological
researches [4]. The Boards of Directors of ACR, the
American Society of Nephrology, and the European
League Against Rheumatism (EULAR) recommended that
the name be changed from “Wegener’s granulomatosis” to
GPA in 2011 [5].
It is estimated that the onset of GPA involves a
genetic background with additional environmental fac-
tors (Staphylococcus aureus infection [6], silica, etc.)
that leads to the production of ANCA, resulting in
the excessive activation of neutrophils and causing
vascular disorders [7]. Of ANCAs, an autoantibody
that acts on proteinase 3 (PR3) is specially noted as
the factor leading to the onset of GPA. It is thought
that neutrophils are activated under the presence of PR3-
ANCA, and subsequently, inflammatory cytokine, reactive
oxygen, and protease are released from the neutrophils
fixated onto the vascular wall, resulting in the onset of
vasculitis and granulomatous inflammation [8].
Although PR3-ANCA is known as a disease marker
for GPA and myeloperoxidase (MPO)-ANCA is known
as a marker for microscopic polyangiitis (MPA) or eo-
sinophilic granulomatosis with polyangiitis (EGPA), the
transfer of antibodies has been observed within AAV,
and MPO-ANCA positive GPA has been reported. How-
ever, few studies exist regarding MPO-ANCA positive
GPA. The clinical characteristics of MPO-ANCA posi-
tive GPA have not been fully elucidated, nor has the
difference between MPO-ANCA positive GPA and
PR3-ANCA positive GPA, especially with regard to
the details of respiratory tract involvement.
In the present study, we retrospectively reviewed con-
secutive cases of GPA to document any differences in
clinical, radiological, and histopathological features be-
tween PR3-ANCA positive cases and MPO-ANCA posi-




This retrospective study was performed at Kurashiki
central hospital in Kurashiki city, Okayama, Japan. The
diagnosis of GPA was based on EMA algorithm. In this
algorithm, using the ACR classification criteria, CHCC
classification, surrogate markers for vasculitis, and the
presence or absence of ANCA, the cases can be classi-
fied in EGPA, GPA, MPA, and classic PN. Either PR3 or
MPO can be used as correspondent antigen of ANCA.
When histopathological investigation cannot be con-
ducted, surrogate markers for granulomatous inflamma-
tion and necrotizing glomerulonephritis are used for
classification [4]. From December 2000 to July 2014, 16
patients newly diagnosed with GPA based on EMA algo-
rithm were included in the study. One case positive for
both PR3-ANCA and MPO-ANCA was excluded from
the subsequent comparative investigation of clinical,
radiological, and histopathological features because the
number of cases is small. The Ethics Committee of
Kurashiki Central Hospital approved this study protocol.
The Ethics Comitee approved the waiver of each pa-
tient’s consent because it was a retrospective study and
high anonymity was secured.
Clinical and laboratory findings
Clinical data and laboratory results were extracted from
the patients’ medical records. The factors examined were
sex, age, the time from onset to first visit and first visit to
treatment start, the department for the first visit, symp-
toms and signs (according to the items of Birmingham
Vasculitis Activity Score; BVAS) at the time of diagnosis,
and laboratory data (inflammatory markers, serum cre-
atinine, and urine analysis). Disease activity was assessed
by BVAS version 3 [9] at the time of diagnosis.
Radiological findings
Chest computed tomography (CT) findings were reviewed
and interpreted by two pulmonologists (IS, MA) and one
radiologist (TK) blinded to the biopsy results and clinical
outcomes. The presence, extension, and distribution of
the following CT findings were evaluated: small nodules
(major axis diameter less than 10 mm), large nodules (10–
30 mm), mass (more than 30 mm), consolidation, ground
glass opacity, centrilobular nodular shadow, bronchial wall
thickening (each levels of trachea, main bronchi, lobar
bronchi, and segmental/sub-segmental), thickening of
interlobular septa, mediastinal /hilar lymphadenopathy,
and pleural effusion.
Histopathological analysis
Two pathologists reviewed the specimens (nasal mucosa,
lung, and kidney) independently, and determined the
presence of the following findings according to the items
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of ACR classification criteria and CHCC classification:
(1) granuloma/granulomatous inflammation of an artery
or perivascular area, (2) necrotizing vasculitis/glomer-
ulonephritis, and (3) granulomatous inflammation of the
respiratory tract. Moreover, cases of glomerulonephritis
was classified into the categories of focal, crescentic,
mixed, or sclerotic according to the histopathologic clas-
sification of ANCA-associated glomerulonephritis pro-
posed by Berden [10].
Statistical analysis
Categorical data are presented as number (percentage).
Continuous data are presented as the median (interquar-
tile range). Fisher’s exact test was used to compare cat-
egorical data. Mann–Whitney U test was used to compare
continuous data. A p value <0.05 was considered statisti-
cally significant.
Results
Clinical characteristics and laboratory data
In this study, all the patients diagnosed as GPA by the
EMA algorithm were positive for ANCA. Nine patients
were positive for PR3-ANCA, six were positive for
MPO-ANCA, and the remaining one was positive for
both PR3-ANCA and MPO-ANCA. According to the
EMA algorithm, all PR3-ANCA positive cases, three of
six MPO-ANCA positive cases, and one double positive
case met the ACR criteria (Fig. 1). The patients who did
not meet the ACR criteria had neither histology of GPA
nor MPA compatible with the CHCC definition. The
remaining three MPO-ANCA positive cases were diag-
nosed as GPA on the basis of the surrogate markers and
positivity for ANCA without histological proof of granu-
loma or necrotizing vasculitis.
The median age at the time of diagnosis was 62.0 years
for the PR3-ANCA positive group, 64.0 years for the
MPO-ANCA positive group, respectively (Table 1). PR3-
ANCA positive group showed almost equal number of
male and female, whereas MPO-ANCA positive group
included a greater number of female (67 %). In the
PR3-ANCA positive cases, the time from onset to first
visit was shorter than the MPO-ANCA positive cases.
No statistically significant differences of laboratory
data were observed between the two groups. However,
in the MPO-ANCA positive cases, white blood cell
count, neutrophil count, and serum C-reactive protein
levels tended to be higher than the PR3-ANCA posi-
tive cases.
Symptoms and signs at the time of diagnosis
With regard to the symptoms and signs based on the
items of BVAS at the time of diagnosis, no clinically
meaningful differences between PR3-ANCA positive
cases and MPO-ANCA positive cases were observed
(Table 2).
As for upper respiratory tract involvement, the most
common manifestation was paranasal sinusitis in both
groups (44 % in PR3-ANCA positive cases and 67 % in
MPO-ANCA positive cases, respectively), followed by
exudative otitis media (33 % and 50 %, respectively). As
for lower respiratory tract involvement, lung nodules
were the most common manifestation (78 % in PR3-
ANCA positive cases and 100 % in MPO-ANCA positive
cases, respectively).
The median BVAS at the time of diagnosis was 19.0 in
PR3-ANCA positive cases and 16.5 in MPO-ANCA
positive cases, respectively. Neither total scores of BVAS
nor scores for every internal organ differ between PR3-
ANCA positive cases and MPO-ANCA positive cases.
Among the items of BVAS, pulmonary nodules or
masses were the most frequently observed in both
groups.
Radiological findings
Thoracic manifestations were found in all patients
(Table 3). In both groups, nodular shadow was observed
at the highest incidence (78 % in PR3-ANCA positive
cases and 100 % in MPO-ANCA positive cases). Small
nodules (<10 mm) were observed in 34 areas in seven
patients in the PR3-ANCA positive group and 66 areas
Fig. 1 Classification of the patients according to the European Medicine Agency algorithm. According to the EMA algorithm, all PR3-ANCA positive
cases, three of six MPO-ANCA positive cases, and one double-positive case met the ACR criteria. The remaining three MPO-ANCA positive cases were
diagnosed as GPA on the basis of the surrogate markers and positivity for ANCA without histological proof of granuloma or necrotizing vasculitis.
Abbreviations: EMA, European Medicine Agency; ACR, American College of Rheumatology; CHCC, Chapel Hill Consensus Conference
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in five patients in the MPO-ANCA positive group. Large
nodules (≥10 mm, <30 mm) were observed in 12 areas
in three patients in the PR3-ANCA positive group and
63 areas in six cases in the MPO-ANCA positive group.
There were no significant differences in the median
number of small/large nodules per person between PR3-
ANCA positive cases and MPO-ANCA positive cases.
The incidence of cavitation was 2.0 % (two of 100 total
areas) in the small nodules and 6.7 % (five of 75 total
areas) in the large nodules.
The second most common finding was the thickening
of tracheal/bronchial walls (56 % in PR3-ANCA positive
cases and 67 % in MPO-ANCA positive cases). In PR3-
ANCA positive cases, thickening of bronchial wall at the
lobar bronchi level was the most common (44 %),
whereas in MPO-ANCA positive cases thickening of
bronchial wall at the segmental/sub-segmental bronchi
level was the most common (67 %).
Consolidation and centrilobular nodular shadow was
frequently observed in PR3-ANCA positive cases (56 %
and 22 %, respectively). All the other findings, such as
ground glass opacity, thickening of interlobular septa,
lymphadenopathy, and pleural effusion, were more fre-
quently observed in MPO-ANCA positive cases (67 %,
33 %, 50 %, and 33 %, respectively) (Fig. 2).
Biopsy sections and histological findings
Biopsy of nasal mucosa, lung, and kidney was performed
from 16 sections in eight patients of PR3-positive group
and five sections in three patients of MPO-ANCA posi-
tive group (Table 4). The most common biopsy section
was lung (11 specimens), followed by nasal mucosa
(seven specimens), and kidney (three specimens).
Granuloma or granulomatous inflammation of ar-
tery/perivascular area, which is one of the items of
ACR criteria, was detected in six sections (three of
the seven specimens of the lung, two of the six speci-
mens of the nasal mucosa, and one of the three spec-
imens of the kidney) in five cases in the PR3-ANCA
group, whereas one section (one of four specimens of
the lung) was noted in one case in the MPO-ANCA
positive group.
Necrotizing vasculitis/glomerulonephritis was detected
in five sections (two of the seven specimens of the lung,
one of the six specimens of the nasal mucosa, and two
of the three specimens of the kidney) in only five cases
in the PR3-ANCA group. Glomerulonephritis without
necrosis was also detected in one PR3-ANCA positive
case. Granulomatous inflammation of the respiratory
tract was detected in three sections (three of the seven
specimens of the lung) in only three cases in the
Table 1 Summary of the clinical characteristics and laboratory data
PR3-ANCA MPO-ANCA P value
(N = 9) (N = 6)
Age 62.0 (52.0–64.0) 64.0 (57.5–72.0) 0.443
Sex (male/female) 5 / 4 2 / 4 0.608
Time
from onset to first visit 12.0 (3.00–22.0) 28.5 (21.8–43.5) 0.045
from first visit to treatment 34.0 (20.0–50.0) 31.5 (15.0–63.0) 0.679
Department for the first visit (%)
Respiratory medicine 3 (33 %) 4 (67 %) 0.329
Rheumatology 3 (33 %) 2 (33 %)
Nephlorogy 3 (33 %) 0
Labopratory data
White Blood Cell (/μL) 10,600 (8,500–12,000) 13,750 (13,025–14,400) 0.099
Neutrophil count (/μL) 8,578 (6,596–9,434) 11,721 (11,138–13,132) 0.077
Lymphocyte count (/μL) 1,148 (794–1,217) 795 (737–1,274) 0.906
Albumin (g/dL) 3.20 (2.60–3.50) 3.15 (2.65–3.58) 1
Creatinine (mg/dL) 0.70 (0.56–3.34) 0.64 (0.48–0.78) 0.48
C-reactive protein (mg/dL) 8.71 (7.89–9.45) 14.3 (8.83–16.7) 0.195
PR3-ANCA 98.0 (45.0–214) - NA
MPO-ANCA - 61.5 (54.3–83.0) NA
Categorical data are presented as number (percentage), and were analyzed by Fisher’s exact test. Continuous data are presented as the median (interquartile range),
and were analyzed by Mann–Whitney U test. A p value of <0.05 was considered statistically significant
Abbreviations: NA not applicable
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Table 2 Symptoms and signs based on the items of BVAS
PR3-ANCA MPO-ANCA P value
(N = 9) (N = 6)
BVAS (total score) 19.0 (12.0–21.0) 16.5 (14.3–20.3) 0.906
General score 2.00 (0.00–2.00) 2.00 (1.25–2.00) 1.00
Myalgia 0 2 (33 %) 0.143
Arthralgia/Arthritis 2 (22 %) 0 0.486
Fever >38 °C 6 (67 %) 4 (67 %) 1.00
Weight loss >2 kg 1 (11 %) 0 1.00
Cutaneous score 0.00 (0.00–0.00) 0.00 (0.00–1.50) 0.351
Skin vasculitis 1 (11 %) 2 (33 %) 0.525
Mucous membranes/eyes score 0.00 (0.00–3.00) 0.00 (0.00–0.00) 0.261
Significant proptosis 1 (11 %) 0 1.00
Scleritis 2 (22 %) 1 (17 %) 1.00
Conjunctivitis 4 (44 %) 0 0.103
ENT score 4.00 (2.00–6.00) 5.50 (1.25–6.00) 0.806
Bloody nasal discharge 6 (67 %) 1 (17 %) 0.119
Paranasal sinus involvement 4 (44 %) 4 (67 %) 0.608
Conductive deafness 3 (33 %) 2 (33 %) 1.00
Sensorineural hearing loss 3 (33 %) 2 (33 %) 1.00
Purulent nasal discharge* 4 (44 %) 0 0.103
Suddle nose* 1 (11 %) 0 1.00
Nasal septum perforation* 1 (11 %) 0 1.00
Exudative otitis media* 3 (33 %) 3 (50 %) 0.622
Chest score 3.00 (3.00–6.00) 4.50 (3.00–6.00) 0.740
Wheeze 0 1 (17 %) 0.400
Nodules or cavities 8 (89 %) 6 (100 %) 1.00
Pleural effusion 0 2 (33 %) 0.143
Infiltrate 4 (44 %) 1 (17 %) 0.580
Alveolar haemorrhage 0 0 NA
Respiratory failure 0 1 (17 %) 0.400
Cough* 2 (22 %) 5 (83 %) 0.0410
Dyspnea* 0 0 NA
Renal score 4.00 (0.00–12.0) 4.00 (1.00–10.0) 0.851
Hypertension 3 (33 %) 3 (50 %) 0.622
Proteinuria >1+ 5 (56 %) 2 (33 %) 0.608
Haematuria >10 rbc/hpf 4 (44 %) 2 (33 %) 1.00
Cr 125–249 μmol/L 0 1 (17 %) 0.40
Cr 250–499 μmol/L 2 (22 %) 0 0.486
Cr >500 μmol/L 2 (22 %) 1 (17 %) 1.00
Rise in Cr >30 % or Ccr fall >25 % 4 (44 %) 1 (17 %) 0.58
Hemodialysis* 2 (22 %) 1 (17 %) 1.00
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PR3-ANCA group. Finally, only three of thePR3-ANCA
positive cases met the CHCC definition.
According to the histopathologic classification of
ANCA-associated glomerulonephritis proposed by Berden
[10], two of three cases were classified into the crescentic
category (with 50 % of glomeruli with cellular crescents),
whereas one case was classified into the sclerotic category
(50 % globally sclerotic glomeruli).
Treatment and outcomes
Combination therapy with prednisone and cyclophos-
phamide was the most common initial treatment in both
groups (67 % for each) (Table 5). Response to the initial
treatment was observed in all cases except one. The re-
fractory case also improved after adding rituximab.
After the induction of remission, the dose of prednis-
one was decreased gradually; however, relapse was
observed in 56 % (5/9) of PR3-ANCA positive cases and
17 % (1/6) of MPO-ANCA positive cases. Among six
relapsed cases, the initial medication included prednis-
one monotherapy (three cases; recurrence rate 100 %),
combination with prednisone and methotrexate (one
case; recurrence rate 100 %), and combination with
prednisone and cyclophosphamide (two cases; recur-
rence rate 20 %).
During the course of the treatment, cavitation of
nodular shadow was observed only in four areas (all
cases were PR3-ANCA positive). Alveolar hemorrhage
was observed as a manifestation of relapse in one patient
in the PR3-ANCA group; however, this improved after
the combination therapy with prednisone, cyclophospha-
mide, and plasmapheresis.
There were only two fatal cases during the observation
periods (one case for each group). The direct causes
of death were dilated cardiomyopathy and aspiration
pneumonia.
Discussion
In the EULAR recommendation, AAV is defined as
chronic inflammatory disease which lasts for more than
four weeks, where infection and malignant tumors are
excluded, and characteristic histological findings are ob-
served in biopsy or an ANCA-positive result is obtained
[11]. AAV includes MPA, GPA, and EGPA; however, the
Table 2 Symptoms and signs based on the items of BVAS (Continued)
Nervous system score 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.842
Headache 1 (11 %) 1 (17 %) 1.00
Hypertrophic pachymeningitis* 1 (11 %) 0 1.00
Retro-orbital mass* 2 (22 %) 0 0.486
Birmingham Vasculitis Activity Score were presented as total scores and scores for every internal organ. Categorical data are presented as number (percentage),
and were analyzed by Fisher’s exact test. Continuous data are presented as the median (interquartile range), and were analyzed by Mann–Whitney U test.
A p value of <0.05 was considered statistically significant. *; Symptoms and signs not included in the items of BVAS.
Abbreviations: BVAS Birmingham Vasculitis Activity Score; NA, not applicable
Table 3 Comparison of HRCT findings between PR3-ANCA
positive cases and MPO-ANCA positive cases
PR3-ANCA MPO-ANCA P value
(N = 9) (N = 6)
Small nodule (<10 mm)
Patients (%) 7 (78 %) 5 (83 %) 1.00
Unilateral/Bilateral 2/5 0/5 0.470
Number per person 2.0 (1.5–8.0) 6.0 (5.0–14) 0.142
Cavity 1 1 NA
Large nodule (≥10, <30 mm)
Patients (%) 3 (33 %) 6 (100 %) 0.0280
Unilateral/Bilateral 0/3 0/6 NA
Number per person 4.0 (3.5–4.5) 3.0 (2.0–4.8) 0.596
Cavity 2 3 NA
Mass (≥30 mm)
Patients (%) 0 1 (17 %) 0.400
Unilateral/Bilateral 0/0 0/1 NA
Number per person 0 3.0 NA
Cavity 0 2 NA
Consolidation
Patients (%) 5 (56 %) 1 (17 %) 0.287
Unilateral/Bilateral 2/3 1/0 1.00
Ground glass opacity (%) 2 (22 %) 4 (67 %) 0.136
Centrilobular nodular shadow (%) 2 (22 %) 0 0.486
Bronchial wall thickening 5 (56 %) 4 (67 %) 1.00
Trachea (%) 1 (11 %) 0 1.00
Main bronchi (%) 2 (22 %) 2 (33 %) 1.00
lobar bronchi (%) 4 (44 %) 3 (50 %) 1.00
Segmental bronchi (%) 2 (22 %) 4 (67 %) 0.136
Thickening of interlobular
septa (%)
0 2 (33 %) 0.143
Mediastinal/hilar
lymphadenopathy (%)
3 (33 %) 3 (50 %) 0.622
Pleural effusion (%) 1 (11 %) 2 (33 %) 0.525
Categorical data are presented as number (percentage), and were analyzed by
Fisher’s exact test
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proportion of these disorders differs greatly between
Europe/US and Japan [12]. The majority of the AAV
patients in Europe and US have GPA, and 80 to 90 % of
GPA patients have PR3-ANCA [13]. In contrast, the
prevalence of MPA has been reported to be much higher
than GPA in Japan. In addition, more than 80 % of
Japanese AAV patients were MPO-ANCA positive [14].
These epidemiological differences became the back-
ground for the establishment of EMA algorithm [4].
In the present study, 56 % of GPA patients were positive
for PR3-ANCA, 38 % were positive for MPO-ANCA, and
the remaining 6 % were positive for both. According to
the retrospective studies regarding Japanese GPA patients
diagnosed by EMA algorithm, the percentage of PR3-
ANCA positive patients was 39.5–58.3 % and MPO-
ANCA was 33.3–54.6 % [15–17]. High prevalence of
Fig. 2 Representative photographs of computed tomography (CT) scans. a Initial CT scan of 63 y.o. male positive for PR3-ANCA shows a solitary
nodule and wall thickning of lobar bronchi. b Initial high-resolution CT scan of 66 y.o female positive for MPO-ANCA shows several nodules,
ground glass opacity, wall thickning of lobar and segmental bronchi, and pleural effusion
Table 4 Histopathological findings
PR3-ANCA MPO-ANCA
(N = 9) (N = 6)
Nasal mucosa biopsy 6 1
Granuloma of artery/perivascular area 2 -
Necrotizing vasculitis 1 -
No siginificant findings 4 1








Vasculitis (without necrosis)* 1 1
No siginificant findings 4 2
Renal biopsy 3 0
Granuloma 1 -









The specimens of nasal mucosa, lung, and kidney were histopathologically
reviewed according to the items of ACR classification criteria and CHCC
classification. *; Meaningful but not diagnostic finding. Glomerulonephritis
were classified into the categories of focal, crescentic, mixed, or sclerotic
according to the histopathologic classification of ANCA-associated
glomerulonephritis proposed by Berden.
Table 5 Treatment and outcomes
PR3-ANCA MPO-ANCA
(N = 9) (N = 6)
Initial treatment
Prednisone + Cyclophosphamide +
Hemodialysis
1 0
Prednisone + Cyclophosphamide 5 4
Prednisone +Methotrexate 1 0





for meintenance therapy 0 3
for uncontrolled disease activity 1 0
Methotrexate 1 0
Ritiximab 2 0




alveolar hemorrhage 1 0
The details of initial treatment, additional treatment, and outcomes for the
patients in each group were specified
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MPO-ANCA positive GPA in Japanese was consistently
noted, whereas the proportion of MPO-ANCA positive
patients was 2.6–13 % in Europe [18, 19]. These differ-
ences may be due, in part, to genetic factors. A genome-
wide association study of AAVs in European Caucasian
patients reported that PR3-ANCA was associated with
HLA-DP and genes encoding α1-antitrypsin (SERPINA1)
and proteinase 3 (PRTN3), whereas MPO-ANCA was as-
sociated with HLA-DQ [20]. Among these, the prevalence
of HLA-DPB1*0401 allele was higher in patients with
PR3-ANCA associated vasculitis than in patients with
MPO-ANCA associated vasculitis or healthy controls.
This allele is also less frequent in Japan, China and US
African Americans; these are three populations where
PR3-ANCA vasculitis is less common than in Europe [21].
In addition, Watts et al. reported that HLA-DPB1*0401
allele frequencies was associated with GPA incidence, and
may help explain variations in GPA incidence between
populations [22].
With regard to the baseline characteristics, the MPO-
ANCA positive group included a greater number of
females (67 %). Many studies of GPA showed a male
predominance or almost equal numbers of males and
females [1, 18, 19, 23]. However, according to the retro-
spective multi-center study of Japanese patients with
GPA or MPA [16], 82 % (14/17) of MPO-ANCA positive
GPA were female, a significantly greater population
than for PR3-ANCA. Another retrospective study of 24
Japanese patients with GPA also showed that 87.5 % were
female [15], consistent with the results of our study.
In the PR3-ANCA positive cases, the time from onset
to first visit was significantly shorter than the MPO-
ANCA positive cases. On the other hand, although not
statistically significant, markers of inflammatory reaction
tended to be higher in MPO-ANCA positive cases. No
meaningful difference was observed in hemoglobin or
serum albumin, which reflects the degree of exhaustion.
In addition, there were no significant differences in
BVAS. Thus, it cannot be stated which group had higher
disease activity and severity.
At the onset of GPA, respiratory tract involvement is
usually the most prevalent sign. Patients with GPA have
either upper or lower respiratory tract involvement and
majority of patients have both [1, 18, 19, 23, 24],
whereas in patients with MPA, upper respiratory tract
involvement does not occur and pulmonary involvement
is usually manifested by alveolar hemorrhage. Character-
istics of respiratory tract involvement in MPO-ANCA
positive GPA have not been fully clarified until now. In
the present study, high frequency of upper respiratory
tract involvement was also noted in MPO-ANCA posi-
tive cases (67 %) as well as PR3-ANCA positive cases
(89 %). As for BVAS at the time of diagnosis, neither
total scores nor the scores for every internal organ differ
between PR3-ANCA positive cases and MPO-ANCA
positive cases. In a retrospective study of 24 Japanese
cases of GPA, MPO-ANCA positive cases had nose and
sinus involvement less frequently compared to PR3-
ANCA positive cases [15]. On the contrary, retrospective
multi-center study of Japanese patients with GPA or
MPA showed that MPO-ANCA positive cases tended to
have ear involvement more frequently, reflected in the
fact that otitis media was significantly higher than in
PR3-ANCA positive cases [16]. However, neither of the
tendencies was observed in the present study, indicating
that further investigation is required.
With regard to chest CT imaging, no significant differ-
ences were observed in the findings between PR3-
ANCA positive cases and MPO-ANCA positive cases.
Lohrmann et al. investigated CT images for 57 cases of
Wegener’s granulomatosis and reported that the most
frequently observed finding is nodular shadow at 89 %,
followed by thickening of bronchial walls at 56 % [25].
However, to the best of our knowledge, no report has
presented the details of radiological findings in MPO-
ANCA positive GPA or compared them with those of
PR3-ANCA positive cases. Incidence of nodular shadows
(78 % in PR3-ANCA positive cases and 100 % in MPO-
ANCA positive cases) and thickening of trachea or bron-
chial walls (56 % in PR3-ANCA positive cases and 67 %
in MPO-ANCA positive cases) reported in this study is
close to the results reported in the previous studies of
GPA. There were no significant difference in the median
number of small/large nodules per person between PR3-
ANCA positive cases and MPO-ANCA positive cases.
On the other hands, less common findings including
ground glass opacity, thickening of interlobular septa,
lymphadenopathy, and pleural effusion, were more fre-
quently observed in MPO-ANCA positive cases in the
present study. In addition, bronchial wall thickning from
the main bronchi level to the segmental/sub-segmental
bronchi level tended to be more conspicuous in MPO-
ANCA positive cases. Further investigation is required
on whether these differences were accidental occurrence
due to the small sample number.
One report noted that cavitation is observed in ap-
proximately 30 to 50 % of nodules [26]; however, in the
present study the incidence of cavitation was found to
be low. In some cases, cavities were formed during the
course of the treatment, suggesting that a certain period
of time is required for cavities to form in the nodular
shadows. It is also possible that as a result of using EMA
algorithm, the disorder is discovered at an early stage,
before the cavities are formed.
With respect to biopsy sections and histological find-
ings, the detection rate of diagnostic findings, such as
granuloma/granulomatous inflammation of an artery/peri-
vascular area, necrotizing vasculitis/glomerulonephritis,
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granulomatous inflammation of the respiratory tract, was
the highest for biopsy of the kidney (66 %), followed by
the lung (40 %) and nasal mucosa (29 %). Significant
findings leading to the diagnosis of GPA are rarely seen in
specimens from the upper respiratory tract, as previously
reported [27–29]. For lung biopsy, the detection rate
of diagnostic findings was 100 % for cases where
video-assisted thoracic surgery (VATS) was performed.
TBLB or echo/CT-guided biopsy resulted in a lower
detection rate (20 %, 33 %, and 0 %, respectively). Mean-
ingful but not diagnostic findings such as vasculitis
without necrosis were observed in small specimens by
TBLB and nasal mucosa. These results suggest that
sufficient tissue is necessary for successful pathological
verification.
However, histopathological investigation cannot be
conducted in some cases; thus, establishment of useful
surrogate marker is desired. In this study, the most com-
mon surrogate markers defined in the EMA algorithm
were fixed pulmonary infiltrates, nodules, or cavitation
present for >1 month (78 % in PR3-ANCA positive cases
and 86 % in MPO-ANCA positive cases, respectively),
followed by bronchial stenosis (33 % and 50 %, respect-
ively) and chronic sinusitis, otitis media, or mastoiditis
for >3 months (56 % and 67 %, respectively) (Table 6).
The detection rate of these markers in MPO-ANCA
positive cases was almost the same as that of PR3-
ANCA positive cases. Thus, investigation of respiratory
tract involvement according to these surrogate markers
will assist the diagnosis of GPA in the cases without
histological proof of granuloma/necrotizing vasculitis
even in MPO-ANCA positive cases.
The prognosis of AAV markedly improved with the
combination therapy of high-dose steroids and cyclo-
phosphamide [4]. In the present study, all the patients
initially treated with prednisone monotherapy or com-
bination with prednisone and methotrexate relapsed
during the treatment course. On the other hand, the rate
of relapse was only 20 % in patients initially treated with
prednisone and cyclophosphamide.
In addition, the recent randomized trial of rituximab
showed that rituximab therapy was superior to cyclo-
phosphamide treatment in relapsing cases of AAV [30].
In the present study, rituximab was administered in two
cases; one case was refractory to the initial combination
therapy with prednisone and cyclophosphamide, and the
other case was refractory to prednisone and cyclophos-
phamide started after relapse. Both cases improved im-
mediately by addition of rituximab, and no relapse has
occurred as of this writing. Moreover, rituximab was as
Table 6 Details of the items applied to each patient according to the EMA algorithm
PR3-ANCA (N = 9) MPO-ANCA (N = 6) PR3 +MPO (N = 1)
ACR criteria
1 item abnormal chest radiograph 0 3 (50 %) 0
2 items purulent/bloody nasal discharge + granuloma formation 2 (22 %) 1 (17 %) 0
abnormal chest radiograph + abnormal urinary sediment 1 (11 %) 1 (17 %) 1 (100 %)
3 items purulent/bloody nasal discharge + abnormal chest
radiograph + granuloma formation
3 (33 %) 0 0
abnormal chest radiograph + abnormal urinary
sediment + granuloma formation
1 (11 %) 0 0
purulent/bloody nasal discharge + abnormal chest
radiograph + abnormal urinary sediment
2 (22 %) 1 (17 %) 0
CHCC criteria
0 item 4 (44 %) 6 (100 %) 1 (100 %)
1 item granuloma formation 0 0 0
necrotizing vasculitis 2 (22 %) 0 0
2 items granuloma formation + necrotizing vasculitis 3 (33 %) 0 0
Surrogate marker
fixed pulmonary infiltrates, nodules, or cavitations (>1 month) 7 (78 %) 5 (86 %) 1 (100 %)
bronchial stenosis 3 (33 %) 3 (50 %) 1 (100 %)
bloody nasal discharge and crusting (>1 month), or nasal ulceration 4 (44 %) 0 0
chronic sinusitis, otitis media, or mastoiditis (>3 months) 5 (56 %) 4 (67 %) 1 (100 %)
retro-orbital mass or inflammation (pseudotumour) 2 (22 %) 0 0
saddle nose deformity/destructive sinonasal disease 1 (11 %) 0 0
Abbreviations: EMA European Medicine Agency, ACR American College of Rheumatology, CHCC Chapel Hill Consensus Conference
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effective as continuous conventional immunosuppressive
therapy in the patients with severe AAV [31]. In future,
initial intensive treatment including rituximab may lead
to favorable prognosis.
In the present study, the rate of relapse in MPO-
ANCA positive cases was lower than that of PR3-ANCA
positive cases (17 % and 56 %, respectively). Relapses are
more common in patients with GPA (25 to 80 % of pa-
tients) than in those with MPA, in whom relapse has
been reported in 8 % at 18 months [32]. According to
the community-based cohort study of 350 patients with
newly diagnosed AAV, the positivity for PR3-ANCA and
involvement of the lung and the upper respiratory tract
were associated with relapse [33]. Even among patients
of GPA, MPO-ANCA positive cases may be less likely to
relapse than PR3-ANCA positive cases.
Limitations of the present study include the small
number of patients investigated and possible deviation
of patient distribution. Another limitation is insufficient
histopathological investigation in MPO-ANCA positive
cases. The short observation period is also a problem
when assessing long-term prognosis.
Conclusions
In the present study, a high prevalence of MPO-ANCA
positive GPA was consistently noted, which is higher in
Japan than in Europe or the US. No significant dif-
ferences of clinico-radiological findings were observed
except for the prevalence of relapse between the PR3-
ANCA positive cases and MPO-ANCA positive cases,
suggesting that the type of ANCA may be of little help
to the diagnosis of GPA. Examination for granulomatous
findings in the upper and lower respiratory tract is very
important even in MPO-ANCA positive cases. There is
a need to accumulate more cases and conduct a further
investigation in the future.
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